SA-205

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameSA-205
Drug Alias NameSA-205
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionEphrin type-A receptor 2 modulators
TargetsEphrin type-A receptor 2
Therapy Area/IndicationsLung NeoplasmsCarcinoma, Renal CellGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Sian Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Sian Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsCarcinoma, Renal CellGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A